Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Ann Hematol. 2017 Mar;96(3):501-504. doi: 10.1007/s00277-016-2892-7. Epub 2016 Dec 3.

Authors

Zimu Gong^{1

2}, Lan Zheng¹, Zhenya Tang¹, Zi Chen¹, Wei Wang¹, Shi Bai¹, Guilin Tang¹, L Jeffrey Medeiros, Shimin Hu³

Affiliations

¹ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
² Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
³ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. shu1@mdanderson.org.

PMID: 27915425
DOI: 10.1007/s00277-016-2892-7

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Genetic Variation / drug effects
Genetic Variation / genetics*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Male
Middle Aged
Philadelphia Chromosome* / drug effects
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / metabolism
Young Adult

Substances

Protein Kinase Inhibitors
Protein-Tyrosine Kinases